Spyre Therapeutics Dividends

SYRE Stock   27.00  0.50  1.82%   
The current year's Dividend Paid And Capex Coverage Ratio is expected to grow to -2,304. Spyre Therapeutics' past performance could be the main factor of why investors trade Spyre Therapeutics stock today. Investors should clearly understand every aspect of the Spyre Therapeutics dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Spyre Therapeutics' dividend schedule and payout information. Spyre Therapeutics dividends can also provide a clue to the current valuation of Spyre Therapeutics.
Last ReportedProjected for Next Year
Dividend Paid And Capex Coverage Ratio-2.4 K-2.3 K
One of the primary advantages of investing in dividend-paying companies such as Spyre Therapeutics is that dividends usually grow steadily over time. As a result, well-established companies that pay dividends typically increase their dividend payouts yearly, which many long-term traders find attractive.
  
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Spyre Therapeutics must own a stock before its ex-dividend date to receive its next dividend.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(37.90)
Return On Assets
(0.39)
Return On Equity
(0.92)
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Compare Dividends Across Peers

Specify up to 10 symbols: